← Eichor
Study identifier: NCT07504146 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Orienting Study

Condition: CPPD - Calcium Pyrophosphate Deposition Disease · Gout  ·  Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

PhaseN/A
Planned participants450
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study at IRCCS Galeazzi - Sant'Ambrogio Hospital involves patients with gout, CPPD, and osteoarthritis as a control group. Patients will receive routine care with regular clinical, laboratory, and imaging assessments every six months, alongside urgent visits as needed. The study aims to understand crystal deposits in joints and blood vessels and monitor their progression over time, assessing how these deposits respond to standard treatments and if they are associated with cardiovascular complications. Data will be collected from medical records over a follow-up period of up to 10 years, offering long-term insights into disease impact and treatment effectiveness.

This description comes directly from the study's public registry record.

Talk to the study team

Georgios Filippou, MD  ·  0039 0283502707  ·  georgios.filippou@grupposandonato.it

Silvia Sirotti, MD  ·  0039 0283502708  ·  silvia.sirotti@grupposandonato.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Ospedale Galeazzi-Sant'AmbrogioMilan, Milano, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07504146